The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Ozempic and other GLP-1 agonists are helping millions with weight loss but concerns grow over their long-term effects. Recent ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and cardiovascular death among adults with type 2 diabetes and chronic kidney ...

The US Food and Drug Administration (FDA) approval is based on the clinical trials that showed how Ozempic, the diabetes drug ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

GLP1-based obesity medicines, such as Ozempic and Wegovy, have surged in popularity and become the subject of intense public ...